Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients

Current Medical Research and Opinion

Volumn 29, Issue 5, 2013, Pages 569-577

  Butler, Kathleen ^a   Maya, Juan ^a   Teng, Renli ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Dyspnea; Exercise test; Respiratory function tests; Ticagrelor

Indexed keywords

AR C 124910XX; DRUG METABOLITE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; PLACEBO; SALBUTAMOL SULFATE; TICAGRELOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BREATHING; BREATHING RATE; BRONCHOSPASM; CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPNEA; ELECTROCARDIOGRAPHY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INJECTION SITE INFLAMMATION; LOADING DRUG DOSE; LUNG FUNCTION; LUNG VENTILATION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NOSE OBSTRUCTION; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL; REST; SIDE EFFECT; SINGLE DRUG DOSE; SPIROMETRY; STOMACH DISCOMFORT; THORAX PAIN; TIDAL VOLUME; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADENOSINE; AGED; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RESPIRATORY RATE; RESPIRATORY TRANSPORT;

EID: 84876253831     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.781502     Document Type: Article

References (35)

1. Hamm CW, Bassand J-P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32:2999-3054
2. Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non- ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):670-707S
3. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27:259-74
4. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
5. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47, reply 1505-6
6. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-51
7. Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;56:185-93
8. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet Inhibition and Patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605
9. Storey RF, Becker RC, Harrington RA, et al. Pulmonary function in patients with acute coronary syndromes treated with ticagrelor or clopidogrel from the PLATelet inhibition and patient Outcomes (PLATO) pulmonary function substudy. Am J Cardiol 2011;108:1542-6
10. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010;70:65-77
11. Teng R, Mitchell P, Butler R. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol 2013;69:477-87
12. Rossi A, Ganassini A, Tantucci C, et al. Aging and the respiratory system. Aging (Milano) 1996;8:143-61
13. Muskulus M, Slats AM, Sterk S, et al. Fluctuations and determinism of respiratory impedance in asthma and chronic obstructive pulmonary disease. J Appl Physiol 2010;109:1582-91
14. American Thoracic Society. Standardization of spirometry,1994 update. Am J Respir Crit Care Med 1995;152:1107-36
15. Mahler DA, Horowitz MB. Perception of breathlessness during exercise in patients with respiratory disease. Med Sci Sports Exerc 1994;26:1078-81
16. O'Donnell DE, Sanii R, Giesbrecht G, et al. Effect of continuous positive airway pressure on respiratory sensation in patients with chronic obstructive pulmonary disease during submaximal exercise. Am Rev Respir Dis 1988;138:1185-91
17. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1557-65
18. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. Am Rev Respir Dis 1993;148:1351-7
19. Sillé n H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B 2010;878:2299-306
20. Brilique, summary of product characteristics, 2010. Available at: http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001241/WC500100494.pdf [Last accessed 12 January 2012]
21. Brilinta, US full prescribing information, July 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022433s000lbl.pdf [Last accessed 12 January 2012]
22. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Resp J 2006;28:1245-57
23. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability, and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010;66:487-96
24. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-6
25. Teng R, Mitchell P, Butler R. Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P45 2C9 substrate, in healthy volunteers. Int J Clin Pharmacol Ther 2013; [Epub ahead of print]
26. Serebruany VL. Dyspnea after AZD6140: safety first? Eur Heart J 2006;27:1505
27. Tomoda H. Ticagrelor versus clopidogrel in acute coronary syndromes. N Engl J Med 2009;361:2385, author reply 2387-8
28. Wittfeldt A, Emanuelsson H, Brandup-Wognsen G, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans - a singlecenter, randomized, double-blind, placebo-controlled, crossover study using transthoracic color Doppler echocardiography. J Am Coll Cardiol 2013;61:723-7
29. Burki NK, Dale WJ, Lee LY. Intravenous adenosine and dyspnea in humans. J Appl Physiol 2005;98:180-5
30. Nylander S, Femia E, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost 2013 [Submitted]
31. Plagemann PG. Na(+)-dependent, concentrative nucleoside transport in rat macrophages. Specificity for natural nucleosides and nucleoside analogs, including dideoxynucleosides, and comparison of nucleoside transport in rat, mouse and human macrophages. Biochem Pharmacol 1991;42:247-52
32. Ward JL, Sherali A, Mo ZP, et al. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem 2000;275:8375-81
33. van Giezen JJJ, Sidaway J, Glaves P, et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperaemia responses in a canine model. J Cardiovasc Pharmacol Therap 2012;17:164-72
34. Molina-Arcas M, Casado FJ, Pastor-Anglada M. Nucleoside transporter proteins. Curr Vasc Pharmacol 2009;7:426-34
35. Storey RF, Becker RC, Harrington RA, et al. Characterisation of dyspnea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011;32:2945-53